Latest news with #JHVEPhoto
Yahoo
11-06-2025
- Business
- Yahoo
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity. Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization. Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately before the start of IND-enabling studies. Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. Deep Apple will be eligible to receive up to $812 million in payments and potential royalties on sales of any products that emerge from the collaboration. Recently, the Danish pharma giant initiated a Phase 3 trial to evaluate the efficacy and safety of cagrilintide sc combined with semaglutide sc (CagriSema sc) once weekly for weight management and long-term weight maintenance in obese participants. The two-part study in around 600 participants will last about 3 years and 3 months. In March, Novo Nordisk announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema compared to placebo. After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose. When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo. Last week, Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN) released interim results from the ongoing Phase 2 COURAGE trial evaluating Regeneron's trevogrumab (anti-GDF8/anti-myostatin) with semaglutide (GLP-1 receptor agonist) with or without garetosmab (anti-activin A) for obesity. The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to the loss of lean mass. Price Action: NVO stock is up 0.04% at $79.36 at the last check Wednesday. Read Next:Photo by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NOVO NORDISK (NVO): Free Stock Analysis Report This article Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
New York Post
07-06-2025
- Business
- New York Post
Beloved UWS eatery Jacob's Pickles shuttered for roaches, rats, sewage
Upper West Side eatery Jacob's Pickles was abruptly shuttered this week following a slew of icky code violations. The Department of Health temporarily closed the Southern-style dining hotspot after the place showed evidence of rats and roaches. The restaurant was also cited for having an 'improper, inadequate, or unapproved' sewage disposal system. An inspection report revealed that the venue, located at 509 Amsterdam Ave. between 84th and 85th Streets, also allegedly failed to properly protect 'food, supplies, or equipment' from possible contamination sources. The shutdown took effect Wednesday with a statement from the restaurant claiming they'll be back open come Monday. 3 The Jacob's Pickles website said the restaurant was closed for renovations. Photo: Eilon Paz 'While unexpected, we're genuinely grateful this issue was brought to our attention,' the statement read. 'With the guidance of the health department, we uncovered underlying structural issues that contributed to unforeseen facility maintenance challenges. 'The safety of our guests and staff is always our top priority, and we will not reopen until every concern is resolved in full compliance with NYC Health Code standards,' the statement concluded. 3 Health inspectors shut the restaurant down Wednesday. JHVEPhoto – 3 Inspectors found evidence of rats living in the restaurant. Katsiaryna – The restaurant's website stated that Jacob's Pickles was closed for renovations and 'will open in a few days.' Jacob's Pickles has had a C rating with the Department of Health since December. Owner Jacob Hadjigeorgis said in May 2024 he would move the American restaurant to a new location at 688 Columbus Ave., between 93rd and 94th Streets, after which he planned to open a new bar, Velvet Cowboy, inside the space Jacob's Pickles had occupied. It's unclear if Hadjigeorgis' plans have changed.
Yahoo
09-05-2025
- Business
- Yahoo
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported first-quarter adjusted earnings of $1.70 per share on Friday, up from $1.21 a year ago, beating the consensus of $1.38 per share. The company reported sales of $197.12 million, up 43.4% year over year, beating the consensus of $180.68 million. On an organic basis, excluding the acquisition of Alimera, total net revenues grew 31.7% year-over-year. Net revenues for rare diseases, which include Cortrophin gel, Iluvien, and Yutiq, increased by 86.7% to $69.0 million. Cortrophin Gel net revenues increased 43.1% to $52.9 million, driven by increased the quarter, the company saw increasing demand with the highest number of new patient starts and new cases initiated since launch. Cortrophin Gel experienced growth across existing and new prescribers, and ANI continued to expand the overall base of Cortrophin Gel prescribers. Iluvien and Yutiq generated net revenues of $16.1 million. Performance for retina assets outside the U.S. was in line with expectations. Performance in the U.S. was impacted by reduced access for Medicare patients due to a lack of funding for third-party co-pay assistance programs, turnover in our sales force, and seasonality. Brands' net revenues decreased 2.2% to $25.1 million, driven by a modest net decrease in volume. Net revenues for Generic pharmaceutical products increased 40.5% to $98.7 million, driven by increased volumes in the base business and contributions from new product launches. Reported gross margin decreased from 64.2% to 62.9%. Adjusted gross margin decreased from 64.4% to 63.1%, primarily due to mix, including significant growth of royalty-bearing products, including Cortrophin Gel. Nikhil Lalwani, President and CEO, commented, 'Based on our first quarter performance and favorable demand trends for Cortrophin Gel and our Generics and Brands portfolio, we are raising our 2025 guidance for total revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP EPS. While we await more visibility on potential pharmaceutical industry-specific tariffs, we believe we are well-positioned based on our strong U.S. footprint with over 90% of our revenues coming from finished goods manufactured in the U.S. and less than 5% of our revenues with direct reliance on China.' Guidance: ANI Pharmaceuticals raised its 2025 revenue guidance from $756 million to $776 million to $768 million to $793 million, versus the consensus of $769.64 million. The company expects adjusted EBITDA of $195 million to $205 million compared to prior guidance of $190 million to $200 million. ANI Pharmaceuticals expects 2025 adjusted EPS of $6.27 to $6.62 versus prior guidance of $6.12 to $6.49 and a consensus of $6.34. Price Action: ANIP stock is down 4.95% to $67.99 at the last check on A Recession, These Waste Management Stocks Have Outperformed S&P 500 Historically Image by JHVEPhoto via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ANI PHARMACEUTICALS (ANIP): Free Stock Analysis Report This article Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
07-03-2025
- Business
- Yahoo
Beyond's Road To Profitability Gets Bumpier: Analyst Warns Of Volatility As EBITDA Milestone Delayed
Needham analyst Bernie McTernan downgraded Beyond, Inc. (NYSE:BYON) from Buy to Hold and removed the prior price forecast of $9. The analyst suggests that the risk-reward for Beyond shares has become less favorable due to significant reductions in revenue estimates over the past six months. While management has successfully cut costs and improved margins, the analyst adds that there was more unprofitable revenue than originally anticipated. According to the analyst, the company is still expected to reach adjusted EBITDA-positive, but this milestone is now pushed out to 2027, which could lead to increased volatility in the stock as the company navigates its turnaround. Also Read: The analyst projects the company to report FY25 EBITDA of $(59.6) million, compared with the previous estimate of $(68.7) million. The analyst acknowledges that margins have performed better than expected, primarily due to improved sales and marketing efforts. Meanwhile, there are concerns about the company's ability to simultaneously accelerate revenue growth while maintaining efficiency in sales and marketing, particularly through leveraging their customer database and email marketing program. In the base case scenario, the analyst credits Beyond for several initiatives, including continued gross margin expansion, better leverage of fixed operating expenses, and more efficient sales and marketing. Despite these positive factors, the analyst remains concerned about the company's adjusted EBITDA performance. Also Read: BYON shares are trading lower by 3.47% to $5.695 at last check Wednesday. Photo by JHVEPhoto via Shutterstock. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Beyond's Road To Profitability Gets Bumpier: Analyst Warns Of Volatility As EBITDA Milestone Delayed originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
